Lilly signs OmniAb ion channel discovery deal with up to $370 million in milestones
- nuaxia
- 11시간 전
- 3분 분량
The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.
Eli Lilly and OmniAb have entered a global collaboration and licence agreement for a new ion channel programme, with OmniAb receiving an undisclosed upfront payment and becoming eligible for up to $370 million in research, development and commercial milestones plus tiered royalties on global net sales.
The partnership applies OmniAb’s discovery platform and specialist ion channel capabilities to a new programme, although the companies have not disclosed the therapeutic target, modality or disease area.
Field | Content |
Alert Type | Deal |
Companies | Eli Lilly and Company; OmniAb |
Deal Type | Global collaboration and licence agreement |
Asset or Company | New undisclosed ion channel discovery programme |
Technology or Modality | Ion channel drug discovery and screening; specific therapeutic modality undisclosed |
Deal Value | Undisclosed upfront payment, plus up to $370 million in research, development and commercial milestone payments and tiered royalties on global net sales. The $370 million represents contingent milestones and is not guaranteed consideration. (Business Wire) |
Development Stage | Discovery |
Geography | Global |
What Happened | On 17 August 2026, OmniAb announced a global collaboration and licence agreement with Eli Lilly for a new ion channel programme. Lilly will gain access to OmniAb’s technology platform and expertise in ion channel discovery and screening. OmniAb will receive an undisclosed upfront payment and is eligible for up to $370 million in research, development and commercial milestones, plus tiered royalties on global net sales. The companies have not disclosed the programme’s therapeutic target or modality. (Business Wire) |
Why It Matters | Ion channels are therapeutically important but technically challenging drug targets because their membrane-bound structures can complicate antigen generation, screening and discovery. OmniAb has built dedicated capabilities around ion channels and transporters alongside its broader therapeutic discovery platform, so the Lilly agreement provides another commercial application of this specialist technology while giving Lilly access to established discovery tools for an otherwise undisclosed programme. (OmniAb) |
Supporting Context | OmniAb’s wider platform combines engineered transgenic animals, computational antigen design, high-throughput screening and computational tools to discover therapeutic antibodies and other target-binding proteins. Its antigen platform can produce full-length membrane proteins, including multi-transmembrane proteins such as ion channels, for use in discovery campaigns. (OmniAb) |
Strategic Rationale | Lilly gains access to OmniAb’s specialised ion channel discovery and screening expertise without the companies disclosing the underlying target or therapeutic approach. OmniAb receives upfront economics while retaining substantial milestone and royalty participation if the partnered programme progresses through development and commercialisation. (Business Wire) |
Potential Impact | Progression of the programme could provide further validation of OmniAb’s ion channel capabilities and generate additional milestone payments, but its therapeutic potential cannot yet be assessed because the target, modality and disease indication remain undisclosed. |
Key Takeaway | Lilly’s agreement puts up to $370 million in contingent milestones behind an OmniAb-enabled ion channel discovery programme, while leaving the underlying target and therapeutic modality undisclosed. |
What to Watch | Disclosure of the therapeutic target, modality or disease area and whether the programme progresses from discovery into preclinical and clinical development, triggering future milestone payments. |
Primary Source | |
Relevant Date | 17 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글